Project Grant R21AI183195

Award Date 6/12/24
Completion Date 4/30/26
Dollars Obligated $874K
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $247,750 to support structural investigations of the SARS-CoV-2 spike protein. The research aims to characterize how glycosylation (the addition of sugar molecules) of the spike protein affects its structure and function, which is critical for virus entry and immune system interactions. This research will...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $243,713 to the University of Massachusetts Medical School (UMass Medical) to conduct a comprehensive analysis of mutations in the SARS-CoV-2 main protease (Mpro) that can impact drug resistance to the COVID-19 treatment nirmatrelvir. The project aims to systematically investigate the interdependence of mutations...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $899,935 to the Scripps Research Institute to identify novel B cell epitopes on the SARS-CoV-2 spike protein and other human coronaviruses. The research aims to uncover conserved and cryptic epitopes that can elicit broadly neutralizing antibodies, with the goal of informing the design of next-generation COVID-19...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $123,356 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis (UC Davis) to characterize the longitudinal dynamics and ecological drivers of coronavirus cross-species transmission in bat populations. The key products and services to be delivered under this grant include: 1) assessing the likelihood of coronavirus cross-species transmission in bats...
This $15,981,588 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases aims to develop pan-coronavirus vaccines. Led by Washington University, the collaborative program includes eleven laboratories seeking to design optimized B and T cell antigens conferring broad immunity against sarbecoviruses and merbecoviruses. The three-year award beginning September 2022 supports three integrated research projects and two centralized cores. Project 1...
This Project Grant award of $1,447,376.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a comprehensive investigation into the dynamics of viruses in wild bat populations. The primary objectives are to: Examine how virus shedding dynamics in bat populations and bat use of anthropogenic structures shape virus exposure risk for humans and domestic animals. Identify local- and...
This $380,320 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the Trustees of the University of Pennsylvania to elucidate the lineage dynamics of optimal human CD8 T cell responses to SARS-CoV-2 and how CD8 T cell homeostasis is altered in Long COVID. The key products of this 3-year project include: Defining human memory CD8 T cell differentiation...
This $1.8 million project grant from the National Science Foundation's Biological Sciences program (CFDA 47.074) will fund research at Cornell University to develop single molecule tools and techniques for studying coronavirus membrane fusion. The goal is to understand the relationship between coronavirus fusion peptide sequence and target host cell membranes at the nanoscale. Specifically, the awardee will identify and measure the physicochemical interactions between the coronavirus spike...
This Project Grant award of $755,225.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a unique vaccine to prevent future pandemics caused by emerging coronavirus (CoV) strains. The goal is to design a mucosal CoV vaccine that targets conserved CoV antigens (S2, M, N) to induce protective T-cell responses, particularly tissue-resident memory T cells in the upper...
This Project Grant award of $190,058 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the role of the protein ADAM9 in the immune response to SARS-CoV-2 infection and its impact on lung injury in severe COVID-19 cases. The research will be conducted at the University of Massachusetts Medical School and builds on the candidate's previous work on the ADAM9/MDA5 innate immune pathway. The findings are expected...

STRUCTURE-FUNCTION ANALYSIS OF HUMAN AND BAT CORONAVIRUS SPIKE PROTEINS - PROJECT SUMMARY/ABSTRACT THE COVID-19 PANDEMIC HAS AFFECTED OVER 690 MILLION PEOPLE WORLDWIDE AND CAUSED 6.9 MILLION DEATHS. ALTHOUGH THE RECENT VARIANTS ARE LESS INFECTIOUS AND CAUSE LOWER MORTALITY THAN EARLIER ONES, DIAGNOSED ACTIVE CASES ARE AS HIGH AS 20 MILLION WORLDWIDE. SARS-COV-2 SPIKE PROTEIN IS CONTINUOUSLY ACCUMULATING MUTATIONS. OUR EARLIER PUBLISHED STUDIES ON ITS RECEPTOR-BINDING DOMAIN (RBD) SHOWED THAT INCREASED RECEPTOR BINDING AND ESCAPE FROM NEUTRALIZING ANTIBODIES DIRECT THE NATURAL SELECTION OF MUTATIONS. HOWEVER, MUTATIONS HAVE ALSO BEEN FOUND IN OTHER REGIONS OF THE SPIKE PROTEIN, AND THE ROLE OF THESE NON-RBD MUTATIONS IS NOT WELL UNDERSTOOD. COMPUTATIONAL MODELS PROPOSE A LONG-RANGE ALLOSTERIC COMMUNICATION BETWEEN DIFFERENT PARTS OF THE SPIKE PROTEIN. DURING THIS 2-YEAR PROPOSAL PERIOD, WE WILL DESIGN EXPERIMENTS TO TEST THE ROLE OF LONG-RANGE COMMUNICATION BY PROBING THE EFFECT OF DISTANT MUTATIONS ON RBD BINDING TO ACE2 AND TO NEUTRALIZING ANTIBODIES (AIM 1). SPIKE PROTEIN IS A TRIMER AND EXISTS IN MULTIPLE CONFORMATIONS WITH INDIVIDUAL RBDS EITHER ACCESSIBLE OR INACCESSIBLE TO ACE2 AND ANTIBODIES. WE WILL PROBE THE RELATIVE POPULATIONS OF THE FOUR CONFORMATIONAL STATES OF THE SPIKE PROTEIN AND THE EFFECT OF MUTATIONS. IN ADDITION TO SARS-COV-2 EMERGED IN 2019, TWO OTHER CORONAVIRUSES (COVS) HAVE CAUSED SEVERE DISEASE: SARS-COV EMERGED IN 2003 AND MERS- COV IN 2012. THOUGH BASED ON ONLY THREE DATA POINTS, THE DATA SUGGESTS ANOTHER COVID OUTBREAK MIGHT BE IMMINENT WITHIN THE NEXT TEN YEARS. HUMAN CORONAVIRUSES (COVS) ARE WIDELY CONSIDERED TO HAVE ORIGINATED FROM BATS, AND HENCE, MULTIPLE EFFORTS WORLDWIDE HAVE BEEN FOCUSED ON IDENTIFYING BAT COVS CAPABLE OF INFECTING HUMANS. SO FAR, ABOUT 700 BAT COVS WITH UNIQUE SPIKE PROTEINS HAVE BEEN IDENTIFIED, AND IT IS CRUCIAL TO DETERMINE WHICH RECEPTOR PATHWAYS THEY MIGHT USE TO INFECT HUMANS IN ORDER TO DEVELOP EFFECTIVE THERAPIES. TO BEGIN WITH, WE WILL EXAMINE WHICH OF THESE BAT COV SPIKE PROTEINS MIGHT USE THE ACE2 (SARS-COV/SARS- COV-2) AND DPP4 (MERS-COV) PATHWAYS BY COMBINING BIOINFORMATIC SEQUENCE ANALYSIS AND DETERMINING THE RELATIVE BINDING AFFINITIES (AIM 2). THESE ASSAYS WILL BE FURTHER APPLIED TO DETERMINE WHICH OTHER RECEPTOR PATHWAYS BAT COVS MIGHT USE TO INFECT THE HUMAN RESPIRATORY SYSTEM. THE MOLECULAR KNOWLEDGE GAINED DURING THIS PROPOSAL WILL HELP US IN PREDICTING THE EVOLUTION OF THE CURRENT SARS-COV-2 VIRUS AND ANY FUTURE COVID OUTBREAKS, WHICH WILL FINALLY LEAD TO DEVELOPING EFFECTIVE THERAPEUTICS THAT CAN NEUTRALIZE MULTIPLE COVS.

Posted 6/12/24, 12:00 AM